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Background
Allergic Rhinitis (AR) is a worldwide spread disease and
has an important impact on social life, sleep quality
(SQ), school and work productivity and huge costs.
ISMAR was designed to identify attitudes and trends
among physicians managing AR in different parts of the
world. ISMAR 2 is the second phase.
Methods
ISMAR is an international, multicenter, non-interven-
tional, cross-sectional study conducted in adults and
children (≥ 6 years) with physician diagnosis-AR of at
least 1 year of duration. Physicians recruited consecutive
patients to whom the ISMAR questionnaire was admi-
nistered. Data collection was performed during a single
visit. Other 2 additional documents (the investigator’s
questionnaire and Case Record Form) were also filled
in. Statistical analysis was descriptive. For statistical
inferences, Student tor Wilcoxon test were performed
according to the variables normality. Herein we show
the results on Patient Optimal Management.
Patients fulfilling the following criteria were consid-
ered as optimally managed:
- Patient education, environmental control and aller-
gen avoidance
- Optimal pharmacological treatment according to
ARIA guidelines
Results
Two thousand three hundred patients (2298 were ana-
lyzed), mean age 28.8 ± 15.9 years, 54.4% of males were
included in 5 new countries and in 4 countries (new
centres) that already participated in ISMAR phase 1.
The nasal symptoms frequency was < 4 days per week
(29.5%), < 4 consecutive weeks (19.5%), > 4 days per
week (29.1%) and > 4 consecutive weeks (21.8%)
[N=2207]. 85.7% of patients had never smoked. Current
smokers suffered most commonly of persistent rhinitis
(61.3%). Patients reported having within the past 12
months, most frequently: recurrent cough (57.1%), noc-
turnal cough (40.8%), recurrent dyspnea/breathlessness
(36.5%), dyspnea/breathlessness after exercise (33.1%),
recurrent wheezing (32.1%), cough after exercise
(29.8%), nocturnal dyspnea/breathlessness (29.5%). AR
symptoms impaired sleep (63.5%), mood (61.9%), physi-
cal activities (50.4%), and working performance (42.1%).
96.3% of patients received recommendations to avoid
allergens and irritants. 96.6% were receiving AR treat-
ment, mainly antihistamines and nasal corticosteroids
but also anti-leukotrienes and nasal and oral deconge-
stants. 55.8% of patients had an optimal treatment.
Patients with a frequency of nasal symptoms > 4 days
per week and > 4 consecutive weeks and those with
recurrent dyspnea/breathlessness appeared as more fre-
quently optimally managed (p<0.001 and P<0.018,
respectively).
Conclusions
This study shows that optimal management in terms of
fulfilling the management recommendations is observed
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in only 55.8% of patients. The application of ARIA
guidelines could be improved in certain countries.
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